mRNA Vaccines Against COVID-19 as Trailblazers for Other Human Infectious Diseases DOI Creative Commons
Rossella Brandi, Alessia Paganelli, Raffaele D’Amelio

и другие.

Vaccines, Год журнала: 2024, Номер 12(12), С. 1418 - 1418

Опубликована: Дек. 16, 2024

mRNA vaccines represent a milestone in the history of vaccinology, because they are safe, very effective, quick and cost-effective to produce, easy adapt should antigen vary, able induce humoral cellular immunity. Methods: To date, only two COVID-19 one RSV have been approved. However, several currently under development for prevention human viral (influenza, immunodeficiency virus [HIV], Epstein–Barr virus, cytomegalovirus, Zika, respiratory syncytial metapneumovirus/parainfluenza 3, Chikungunya, Nipah, rabies, varicella zoster herpes simplex 1 2), bacterial (tuberculosis), parasitic (malaria) diseases. Results: RNA viruses, such as severe acute syndrome coronavirus (SARS-CoV)-2, HIV, influenza, characterized by high variability, thus creating need rapidly circulating strain, task that can easily accomplish; however, speed variability may be higher than time needed vaccine adapted. vaccines, using lipid nanoparticles delivery system, act adjuvants, powerfully stimulating innate well adaptive immunity, both humoral, which is waning, cell-mediated, highly persistent. Safety profiles were satisfactory, considering slight increase prognostically favorable anaphylactic reactions young females myopericarditis males has observed. Conclusions: The pandemic determined shift use RNA: after having used medicine micro-RNAs tumor new era anti-infectious begun, great development, either improve already available, but unsatisfactory, or develop protective against infectious agents no preventative tools realized yet.

Язык: Английский

Temporal profiling of human lymphoid tissues reveals coordinated defense against viral challenge DOI Creative Commons
Matthew L. Coates, Nathan Richoz, Zewen Kelvin Tuong

и другие.

Nature Immunology, Год журнала: 2025, Номер 26(2), С. 215 - 229

Опубликована: Янв. 31, 2025

Язык: Английский

Процитировано

1
SARS-CoV-2 Vaccines: The Advantage of Mucosal Vaccine Delivery and Local Immunity DOI Creative Commons
Joshua Tobias, Peter Steinberger,

Joy Wilkinson

и другие.

Vaccines, Год журнала: 2024, Номер 12(7), С. 795 - 795

Опубликована: Июль 18, 2024

Immunity against respiratory pathogens is often short-term, and, consequently, there an unmet need for the effective prevention of such infections. One infectious disease coronavirus 19 (COVID-19), which caused by novel Beta SARS-CoV-2 that emerged around end 2019. The World Health Organization declared illness a pandemic on 11 March 2020, and since then it has killed or sickened millions people globally. development COVID-19 systemic vaccines, impressively led to significant reduction in severity, hospitalization, mortality, contained pandemic’s expansion. However, these vaccines have not been able stop virus from spreading because restricted mucosal immunity. As result, breakthrough infections frequently occurred, new strains emerging. Furthermore, will likely continue circulate like influenza virus, co-exist with humans. upper tract nasal cavity are primary sites infection thus, mucosal/nasal vaccination induce response virus’ transmission warranted. In this review, we present status both approved those under evaluation clinical trials. our approach B-cell peptide-based applied prime-boost schedule elicit

Язык: Английский

Процитировано

5
Natural and induced immune responses in oral cavity and saliva DOI Creative Commons

Michele Matsuoka,

Salim Abraham Soria,

Julien Rodrigues Pires

и другие.

BMC Immunology, Год журнала: 2025, Номер 26(1)

Опубликована: Апрель 18, 2025

Язык: Английский

Процитировано

0
Why Should Vaccines against Respiratory Diseases Go Mucosal? B Cell Epitope-Based Vaccines against SARS-CoV-2 DOI Open Access
Joshua Tobias, Peter Steinberger,

Joy Wilkinson

и другие.

Опубликована: Июнь 13, 2024

Immunity against respiratory pathogens is often short-term, and consequently there an unmet need for effective prevention of such infections. One infectious disease COVID-19, which caused by the novel Beta coronavirus SARS-CoV-2 that emerged around end 2019. The World Health Organization declared illness a pandemic on March 11, 2020, since then it has killed or sickened millions people globally. development COVID-19 systemic vaccines, impressively led to significant reduction in severity, hospitalization, mortality, con-tained pandemic's expansion. However, these vaccines have not been able stop virus from spreading because restricted mucosal immunity. As result, breakthrough infections frequently occurred new strains emerging. Furthermore, will likely continue circulate and, like influenza virus, co-exist with humans. upper tract nasal cavity are primary sites infection thus, mucosal/nasal vaccination induce response transmission warrant-ed. In this review, we present status approved those under evaluation clinical trials. our approach B-cell pep-tide-based applied prime-boost schedule eliciting both

Язык: Английский

Процитировано

1
mRNA vaccine-induced IgG mediates nasal SARS-CoV-2 clearance in mice DOI Creative Commons
Charlie Fricke, Lorenz Ulrich, Jana Kochmann

и другие.

Molecular Therapy — Nucleic Acids, Год журнала: 2024, Номер 35(4), С. 102360 - 102360

Опубликована: Окт. 16, 2024

Coronavirus disease 2019 (COVID-19) mRNA vaccines that have contributed to controlling the SARS-CoV-2 pandemic induce specific serum antibodies, which correlate with protection. However, neutralizing capacity of antibodies for emerging variants is altered. Suboptimal antibody responses are observed in patients humoral immunodeficiency diseases, ongoing B cell depletion therapy, and aging. Common experimental mouse models altered compartments, such as or deficiency, do not fully recapitulate scenarios declining suboptimal levels humans. We report on immunity a transgenic model restricted virus-specific antibodies. Vaccination C57BL/6-Tg(IghelMD4)4Ccg/J mice unmodified N1mΨ-modified encoding ancestral spike (S) protein subsequent challenge mouse-adapted provided insights into antibody-independent impact titers mucosal immunity. Protection against fatal was independent seroconversion following vaccination, suggesting T cells can compensate levels. In contrast, mRNA-induced IgG nasal conchae limited local viral load progression. Our results indicate parenteral immunization elicit effectively suppress replication, highlighting potential transmission epidemiology.

Язык: Английский

Процитировано

1
Role of IgA1 protease-producing bacteria in SARS-CoV-2 infection and transmission: a hypothesis DOI Creative Commons
Michael W. Russell, Mogens Kilian, Jiří Městecký

и другие.

mBio, Год журнала: 2024, Номер 15(10)

Опубликована: Авг. 29, 2024

Secretory (S) IgA antibodies against severe acute respiratory syndrome (SARS)-CoV-2 are induced in saliva and upper tract (URT) secretions by natural infection may be critical determining the outcome of initial infection. IgA1 (SIgA1) is predominant isotype these secretions. Neutralization SARS-CoV-2 most effectively accomplished polymeric such as SIgA. We hypothesize that cleavage SIgA1 unique bacterial proteases to univalent Fabα antibody fragments with diminished virus neutralizing activity would facilitate descent into lungs cause serious disease also enhance its airborne transmission others. Recent studies nasopharyngeal microbiota patients have revealed significant increases proportions protease-producing bacteria comparison healthy subjects. Similar considerations might apply other viral infections including influenza, possibly explaining original attribution influenza

Язык: Английский

Процитировано

0
Next-Generation SARS-CoV-2 Vaccine Formulations and Alternative Routes of Administration DOI Creative Commons
Tara M Babu, Lisa A. Jackson, Hana M. El Sahly

и другие.

The Journal of Infectious Diseases, Год журнала: 2024, Номер unknown

Опубликована: Окт. 16, 2024

Abstract The development of SARS-CoV-2 next-generation vaccines with the potential for increased effectiveness, durability, breadth, and ability to decrease transmission are public health importance. We highlight alternative routes administration such as mucosal intradermal administration.

Язык: Английский

Процитировано

0
mRNA Vaccines Against COVID-19 as Trailblazers for Other Human Infectious Diseases DOI Creative Commons
Rossella Brandi, Alessia Paganelli, Raffaele D’Amelio

и другие.

Vaccines, Год журнала: 2024, Номер 12(12), С. 1418 - 1418

Опубликована: Дек. 16, 2024

mRNA vaccines represent a milestone in the history of vaccinology, because they are safe, very effective, quick and cost-effective to produce, easy adapt should antigen vary, able induce humoral cellular immunity. Methods: To date, only two COVID-19 one RSV have been approved. However, several currently under development for prevention human viral (influenza, immunodeficiency virus [HIV], Epstein–Barr virus, cytomegalovirus, Zika, respiratory syncytial metapneumovirus/parainfluenza 3, Chikungunya, Nipah, rabies, varicella zoster herpes simplex 1 2), bacterial (tuberculosis), parasitic (malaria) diseases. Results: RNA viruses, such as severe acute syndrome coronavirus (SARS-CoV)-2, HIV, influenza, characterized by high variability, thus creating need rapidly circulating strain, task that can easily accomplish; however, speed variability may be higher than time needed vaccine adapted. vaccines, using lipid nanoparticles delivery system, act adjuvants, powerfully stimulating innate well adaptive immunity, both humoral, which is waning, cell-mediated, highly persistent. Safety profiles were satisfactory, considering slight increase prognostically favorable anaphylactic reactions young females myopericarditis males has observed. Conclusions: The pandemic determined shift use RNA: after having used medicine micro-RNAs tumor new era anti-infectious begun, great development, either improve already available, but unsatisfactory, or develop protective against infectious agents no preventative tools realized yet.

Язык: Английский

Процитировано

0